AADI

BIOADAPTIVES reported modest revenue of $18,278 for the year, with a net loss of $(1,557,898) and net loss per common share of $(0.15), reflecting higher operating expenses and intensified investment in product development and marketing. Gross profit improved to $12,497 versus $4,030 in 2024, but loss from operations widened to $(1,042,173) as operating expenses increased to $1,054,670. The results reflect limited sales activity alongside strategic repositioning of the product portfolio and go-to-market preparations.

Financial Highlights

• Revenue: $18,278 (increase from $12,669 in 2024)
• Gross Profit: $12,497 (improved vs $4,030 in 2024)
• Loss from operations: $(1,042,173) (operating expense increase to $1,054,670)
• Net Loss: $(1,557,898) (worsened from $(899,161) in 2024)
• Net Loss Per Common Share: $(0.15) (vs $(0.11) in 2024)

Business Highlights

• Revenue Growth: Minimal revenue increase to $18,278 in 2025 from $12,669 in 2024, reflecting very limited sales activity.
• Product Pipeline & Branding: Reformulating the full product line with pre-launch activities for MyndMed™, PawPa® Regen, Xcellara™, and Zeranovia™ to build brand presence.
• Channel Expansion: Executed a marketing agreement and acquired inventory for the FDA-cleared Lung Flute™ with plans to target medical, pharmacy, fitness, and senior channels.
• Operational Milestones: Completed a reverse split (1-for-300) and approved a one-for-one stock dividend; leadership transition to CEO James Kneer occurred in 2024.
• Go-to-Market Timing: New product rollouts expected beginning in Q2 2025, supported by ongoing clinical trials and market testing.

Original SEC Filing: BIOADAPTIVES, INC. [ BDPT ] - 10-K - Apr. 14, 2026